100
Views
25
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes

Insulin—Carcinogen or Mitogen? Preclinical and Clinical Evidence from Prostate, Breast, Pancreatic, and Colorectal Cancer Research

, BPharm, , BPharm, , BPharm, , BPharm, , BPharm, , BPharm, , PharmD & , PharmD, BCPS, CDE show all
Pages 158-165 | Published online: 13 Mar 2015

References

  • . Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008:14
  • . Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC, , eds. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill; 2008:1205–1241
  • . American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33( suppl 1):S11–S61
  • . Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–1777
  • . Hemkens LG, Grouven U, Bender R, . Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732–1744
  • . Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009; 52(9):1755–1765
  • . Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52(9):1745–1754
  • . US Food and Drug Administration. Early communication about safety of Lantus (insulin glargine). July 1, 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169722.htm. Accessed September 22, 2009
  • . American Association of Clinical Endocrinologists. AACE response to insulin glargine cancer risk articles in Diabetologia: June 29, 2009. http://media.aace.com/article_display.cfm?article_id=4932. Accessed September 22, 2009
  • . American Diabetes Association. Statement from the ADA on studies suggesting a possible link between insulin glargine and cancer. July 2, 2009. http://professional.diabetes.org/News_Display.aspx?TYP=9&CID=71434. Accessed September 20, 2009
  • . European Association for the Study of Diabetes. Lantus insulin: a possible link with cancer which required further investigation. Dusseldorf, Germany: 2009. http://webcast.easd.org/press/glargine/glargine.htm. Accessed September 22, 2009
  • . Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia. 2009;52(9):1699–1708
  • . Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 2008;8(12):915–928
  • . Watson RT, Kanzaki M, Pessin JE. Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. Endocr Rev. 2004;25(2):177–204
  • . Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during homeostasis. Nat Rev Cancer. 2006;6(3):184–192
  • . Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond). 2009;118(5):315–332
  • . Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505–518
  • . Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–854
  • . Slieker LJ, Brooke GS, DiMarchi RD, . Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia. 1997;40( suppl 2):S54–S61
  • . Kurtzhals P, Schäffer L, Sørensen A, . Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999–1005
  • . Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25(1):41–49
  • . Hoeijmakers JHJ. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475–1485
  • . Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358(5):502–511
  • . Wang LH, Lin B, Jong SM, . Activation of transforming potential of the human insulin receptor gene. Proc Natl Acad Sci U S A. 1987;84(16):5725–5729
  • . Staiger K, Staiger H, Schweitzer MA, . Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia. 2005;48(9):1898–1905
  • . Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol. 2002;21(3):171–179
  • . Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25(1):41–49
  • . Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate. 2002;50(1):1–3
  • . Hsing AW, Chua S Jr, Gao YT, . Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001;93(10):783–789
  • . Chokkalingham AP, Pollak M, Fillmore CM, . Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2001;10(5):421–427
  • . Janssen JA, Wildhagen MF, Ito K, . Circulating free insulin-like growth factor (IGF)-1, total IGF-1, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients with a population-based screening with a 4-year inteval. J Clin Endocrinol Metab. 2004;89(9):4391–4396
  • . Staiger K, Hennige AM, Staiger H, Häring HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res. 2007;39(1):65–67
  • . Hankinson SE, Willett WC, Golditz GA, . Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet. 1998;351(9113):1393–1396
  • . Toniolo P, Bruning PF, Akhmedkhanov A, . Serum insulinlike growth factor-1 and breast cancer. Int J Cancer. 2000;88(5):828–832
  • . Erbel S, Reers C, Eckstein VW, . Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care. 2008;31(6):1105–1111
  • . Fisher WE, Boros LG, Schirmer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res. 1996;63(1):310–313
  • . Stolzenberg-Solomon RZ, Graubard BI, Chari S, . Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294(22):2872–2878
  • . Giovannucci E, Pollak MN, Platz EA, . A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000;9(4):345–349
  • . Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127(4):1044–1050
  • . Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum. 2008;51(5):593–597
  • . Hansen BF. Insulin analogues with increased mitogenic potency—are they safe? Horm Metab Res. 2008;40(6):431–433
  • . Rosenstock J, Fonseca V, McGill JB, . Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009;52(9):1971–1973
  • . Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52(12):2507–2512
  • . Gerstein HC. Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA. 2010;303(5):446–447

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.